Il­lu­mi­na to di­vest Grail, two years af­ter $8B deal was stymied by an­titrust is­sues

Il­lu­mi­na will di­vest its can­cer di­ag­nos­tic sub­sidiary Grail, it an­nounced Sun­day, end­ing a painful years-long saga in which the prized ac­qui­si­tion was held up by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER